Vicatertide  (Synonyms: SB-01; Peniel 2000)

Vicatertide (SB-01, Peniel 2000) is a polypeptide with both competitive inhibitory activity against TGF-β1 and selective inhibitory activity against human factor XIa (hFXIa, with a K_a of 80 nM for hFXIa). Vicatertide binds allosterically to the two binding sites of dimeric hFXI/hFXIa, while directly binding to activated TGF-β1, selectively blocking the Smad1/5/8 pathway and maintaining low-level activation of the Smad2 pathway to enhance the synthesis of type Ⅱ collagen and aggrecan. Vicatertide inhibits thrombus formation in arteriovenous thrombosis models, and also reduces thrombus weight and thrombus incidence in mouse lung cancer models. Vicatertide can be used for research on degenerative disc disease and thrombosis-related diseases^[1][2].

Vicatertide (SB-01) potently and selectively inhibits purified human factor XIa via a mixed allosteric mechanism, with a potency of 130 nM and an efficacy of approximately 90%. It also binds to purified human factor XI with an affinity of approximately 80 nM and forms a 4:1 hFXI::SB-01 co-complex^[1].
Vicatertide acts via a mixed allosteric inhibition mechanism, which dose-dependently decreases the maximum reaction rate (Vmax) of hFXIa and slightly increases the Michaelis constant (KM)^[1].
Vicatertide (Peniel 2000, P2K) (75-125 μM; coincubation with 2 ng/mL TGF-β1) selectively suppresses phosphorylation of Smad1/5/8 while moderately reducing Smad2 phosphorylation in primary bovine intervertebral disc cells, and 125 μM achieves nearly complete inhibition of p-Smad1/5/8^[1].
Vicatertide (125 μM; coincubation with 2 ng/mL TGF-β1) upregulates mRNA levels of COL2A1 and ACAN in primary bovine intervertebral disc cells^[1].
Vicatertide (125 μM; combined with ALK5/ALK1 selective inhibitors) elevates COL2A1 and ACAN transcription mainly via modulating ALK1-Smad1/5/8 cascade rather than ALK5-Smad2 pathway in primary bovine intervertebral disc cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Vicatertide (SB-01) (6 mg/kg; intravenous injection; single administration) significantly reduces thrombus formation in the FeCl₃-induced arterial thrombosis model^[1].
Vicatertide (3, 6 mg/kg; intravenous injection; single administration) significantly reduces thrombus formation in a rat model of tissue thrombin-induced vena cava thrombosis^[1].
Vicatertide significantly reduces thrombus weight and thrombus incidence in mouse lung cancer models^[1].
Vicatertide (Peniel 2000, P2K) (10 μg per disc; intradiscal single injection; single administration) increases %DHI values, improves MRI degeneration grade, lowers histological degeneration score, and elevates nucleus pulposus proteoglycan and collagen contents at 4/8/12 weeks after dosing in rabbit intervertebral disc degeneration models^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

871.03

C₄₂H₆₆N₁₀O₁₀

1251838-01-3

Solid

White to off-white

Leu-Gln-Val-Val-Tyr-Leu-His

LQVVYLH

Room temperature in continental US; may vary elsewhere.

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

• [1]. Sharma C, et al. Discovery and preclinical characterization of SB-01, a novel allosteric inhibitor of human factor XIa. Blood, 2025, 146 (Supplement 1): 16.

  [2]. Kwon YJ, et al. Anabolic effects of Peniel 2000, a peptide that regulates TGF-β1 signaling on intervertebral disc degeneration. Spine (Phila Pa 1976). 2013;38(2):E49-E58.  [Content Brief]